NautaDutilh assisted Batavia Biopharma and First Dutch investments on the sale of a majority interest (ca. 75%) in Leiden based Batavia Biosciences B.V. for approximately EUR 195 million to Korea based CJ Corp. Batavia is a CDMO (Contract Development and Manufacturing Organization) the field of viral vector based biotherapeutics.
Ruud Smits: “This was a great team effort from our NY and Amsterdam based life sciences teams. It was a challenging auction process with many stakeholders, but with a great result for all involved. Given the type of business foreign direct investment approvals play an important role.”
Our team consisted of: Ruud Smits, Jeanine Evertse, Jos Somers, Willem vd Vossen, Nima Lorje, Arnout Koeman, Jasmijn van Koetsveld, Wijnand Bossenbroek, Florine Kuiperi, Frans Ruijs, Pedro Paraguay and Jeroen Boelens.
Het Financieele Dagblad: Koreanen kopen Batavia biosciences voor bijna 200 miljoen
Korea Economic Daily: CJ Cheiljedang to buy Dutch firm Batavia Biosciences for 195 million euros
Econotimes: Korea’s CJ Cheiljedang to buy Dutch firm Batavia Biosciences for $226M
Biopharma Reporter: CJ Cheiljedang set to acquire Batavia Biosciences for $226m